A new study suggests that high doses of vitamin D supplements could help reduce disease activity among multiple sclerosis ...
Columnist Desiree Lama remembers how a best friend helped her with stressful assignments and RRMS symptoms in college.
A small molecule that blocks TYK2 in the brain showed promise for reducing disease activity in mouse models of multiple ...
MUSETTE trial was designed to determine whether a higher dose of the currently approved OCREVUS IV 600 mg would provide ...
“These findings reaffirm that the current Ocrevus IV 600 mg is optimally dosed to significantly slow disability progression,” ...
10d
Live Science on MSNIn a 1st, trial finds vitamin D supplements may slow multiple sclerosis. But questions remain.A new clinical trial has shown for the first time that taking high doses of vitamin D could stave off the progression of ...
Explore more
9d
MedPage Today on MSNDeciding Whether Multiple Sclerosis Treatment Should Be DiscontinuedObservational studies and two randomized controlled trials consistently suggest that, in general, disease recurrence after ...
9d
PsyPost on MSNCan ibogaine repair brain damage in multiple sclerosis? New case reports spark interestIn a recent case report published in Frontiers in Immunology, scientists in Canada described how an experimental treatment ...
5d
Lohud.com, Westchester County on MSNTeacher, 'multiple sclerosis champion' to be honoree at MS fundraiser in WestchesterIt took a decade for Heather Castellani Milboer to be diagnosed with multiple sclerosis. Now, she helps build community for ...
Multiple Sclerosis: Cell-Catching Implant Helps Identify Successful Treatment in Mice Feb. 18, 2025 — A sponge-like implant in mice helped guide a treatment that slowed or stopped a degenerative ...
Deputy Mark Hampton was indicted on charges of Violation of Oath by Public Officer and Violation of the Racketeer Influenced ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III MUSETTE trial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results